Mike Grey and his network of San Diego-based biotech execs are formally notching a new startup debut today.
The company is Reneo Pharmaceuticals, which drew a syndicate together around CEO Niall O?Donnell with $50 million to support their ongoing work on new treatments for genetic mitochondrial diseases.
Today marks their coming out party for the company, but the 12-member team at Reneo ? 7 in the UK and 5 in San Diego ? have been hard at it for more than 2 years. They?ve already steered their way to 2 clinical trials, focusing on REN001, a PPAR-delta agonist being used to treat genetically defined rare mitoch